Synteka Bio신테카바이오
226330 · KOSDAQ · ₩226330 · 신테카바이오
₩1,034▼ ₩25 (2.36%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.4B | ₩121M | ₩123M | ₩244M | ₩317M |
| Operating income | −₩11B | −₩14B | −₩12B | −₩12B | −₩8.9B |
| Net income | −₩17B | −₩7.2B | −₩11B | −₩4.5B | −₩15B |
| Net income to shareholders | −₩17B | −₩7.2B | −₩11B | −₩4.5B | −₩15B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩47B | ₩44B | ₩53B | ₩56B | ₩68B |
| Current assets | ₩17B | ₩13B | ₩22B | ₩37B | ₩58B |
| Cash and equivalents | ₩16B | ₩12B | ₩20B | ₩35B | ₩14B |
| Total liabilities | ₩15B | ₩19B | ₩22B | ₩24B | ₩40B |
| Current liabilities | ₩12B | ₩16B | ₩19B | ₩22B | ₩1.9B |
| Borrowings | ₩7.1B | ₩7.3B | ₩1.8B | ₩10B | ₩8.2B |
| Total equity | ₩32B | ₩25B | ₩31B | ₩31B | ₩28B |
| Shareholders' equity | ₩32B | ₩25B | ₩31B | ₩31B | ₩28B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩11B | −₩11B | −₩8.1B | −₩8.5B | −₩6B |
| Capital spending | ₩11M | ₩5.7B | ₩9.4B | ₩8.4B | ₩7.5B |
| Free cash flow | −₩11B | −₩16B | −₩17B | −₩17B | −₩14B |
Consolidated where available. Amounts in won.
Also known as: Synteka Bio / 신테카바이오 / 226330 / KRX:226330
Source: KRX statistical information